BioNexus Gene Lab Corp. (BGLC)

BioNexus Gene Lab Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2026	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-2.98	-1.6	-2.63	-0.36
Depreciation & Amortization	0.17	0.15	0.11	0.11
Stock-Based Compensation	0.79	0.14	-	-
Other Adjustments	0.17	-0.9	0.58	-0.03
Change in Receivables	0.78	0.15	0.65	0.54
Changes in Inventories	0.71	-0.25	-0.16	0.54
Changes in Accounts Payable	-1.38	0.2	-0.38	-0.12
Changes in Unearned Revenue	-0.09	0.1	-0.02	-0.08
Changes in Other Operating Activities	-0.01	-0.08	0.03	-0.05
Operating Cash Flow	-1.84	-2.09	-1.82	0.55
Capital Expenditures	-0.04	-0.23	-0.15	-0.05
Purchases of Investments	-0.01	-0.49	-0.32	-0.51
Proceeds from Sale of Investments	1.03	1.07	0.03	-
Other Investing Activities	-0.04	0.07	-1.35	0.12
Investing Cash Flow	0.94	0.42	-1.79	-0.45
Issuance of Common Stock	0.27	-	6.26	0.15
Net Common Stock Issued (Repurchased)	0.27	-	6.26	0.15
Other Financing Activities	0.03	0	0.01	-0.04
Financing Cash Flow	0.3	0	6.27	0.11
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.19	0.04	-0.26	-0.21
Net Cash Flow	-0.4	-1.63	2.4	-0.01
Free Cash Flow	-1.88	-2.32	-1.97	0.5
FCF Margin	-25.26%	-24.40%	-20.18%	4.55%
Free Cash Flow Per Share	-1.01	-1.30	-1.37	0.35
Levered Free Cash Flow	-3.62	-1.7	-3.2	-0.01
Unlevered Free Cash Flow	-3.6	-1.68	-3.19	0

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q